Tumor Genetic Analyses of Patients with Metastatic Renal Cell Carcinoma and Extended Benefit from mTOR Inhibitor Therapy

PURPOSE: Rapalogs are allosteric mTOR inhibitors and approved agents for advanced kidney cancer. Reports of clonal heterogeneity in this disease challenge the concept of targeted monotherapy, yet a small subset of patients derives extended benefit. Our aim was to analyze such outliers and explore th...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Voss, Martin H., Hakimi, A. Ari, Pham, Can G., Brannon, A. Rose, Chen, Ying-Bei, Cunha, Luis F., Akin, Oguz, Liu, Han, Takeda, Shugaku, Scott, Sasinya N., Socci, Nicholas D., Viale, Agnes, Schultz, Nikolaus, Sander, Chris, Reuter, Victor E., Russo, Paul, Cheng, Emily H., Motzer, Robert J., Berger, Michael F., Hsieh, James J.
Formato: Artigo
Idioma:Inglês
Publicado em: 2014
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4140619/
https://ncbi.nlm.nih.gov/pubmed/24622468
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-13-2345
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados